You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial

Citation Tools

Article menu
Download PDFPDF
Oral Presentations
Abstract session: RA therapy beyond TNF inhibition
OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Genovese M, van Vollenhoven R, Wilkinson B, et al
OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial
Annals of the Rheumatic Diseases 2013;72:A65.